ASCO 2019: Data strongly support the recent FDA approval of cemiplimab

In this MEDtalk Michael Robert Migden, Texa, present new data about cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma. This study showed, that cemiplimab hassubstantial antitumor activity, durable responses, and acceptable safety profile in patients with locally advanced cutaneous squamous cell carcinoma.